for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cansino Biologics Inc

6185.HK

Latest Trade

327.00HKD

Change

3.00(+0.93%)

Volume

1,480,001

Today's Range

305.40

 - 

342.00

52 Week Range

71.60

 - 

450.00

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Cansino Biologics Says NMPA Has Granted Conditional Marketing Authorization For Ad5-Ncov In Mainland China

Feb 25 (Reuters) - CanSino Biologics Inc <6185.HK>::CANSINO BIOLOGICS INC- NMPA HAS GRANTED CONDITIONAL MARKETING AUTHORIZATION FOR AD5-NCOV IN MAINLAND CHINA.

CanSino Biologics' Prelim 2020 Net Loss Widens To 407 Mln Yuan

Feb 25 (Reuters) - Cansino Biologics Inc <6185.HK>::SAYS PRELIM 2020 NET LOSS WIDENS TO 407.0 MILLION YUAN ($63.09 million) FROM 156.8 MILLION YUAN YEAR EARLIER.

CanSino Biologics Says NMPA Accepted Application For Conditional Marketing Authorization Of AD5-NCOV

Feb 24 (Reuters) - CanSino Biologics Inc <6185.HK>::AD5-NCOV HAS 68.83% EFFICACY AT PREVENTING ALL SYMPTOMATIC COVID-19 DISEASE 14 DAYS AFTER SINGLE DOSE VACCINATION.INTERIM ANALYSIS OF PHASE III TRIAL OF AD5-NCOV SHOWS IT HAS AN OVERALL EFFICACY OF 65.28% AT PREVENTING SYMPTOMATIC COVID-19.AD5-NCOV HAS AN EFFICACY OF 90.07% AT PREVENTING SEVERE DISEASE 28 DAYS AFTER SINGLE DOSE VACCINATION.THE OVERALL EFFICACY OF 65.28% FOR AD5-NCOV IS 28 DAYS AFTER SINGLE DOSE VACCINATION.AD5-NCOV HAS AN EFFICACY OF 95.47% AT PREVENTING SEVERE DISEASE 14 DAYS AFTER SINGLE DOSE VACCINATION.NMPA HAS ACCEPTED CONDITIONAL MARKETING AUTHORIZATION OF AD5-NCOV.

JPMorgan Chase & Co's Long Position In CanSino Biologics Falls To 6.96% - HKEX Filing

Feb 19 (Reuters) - Hong Kong stock exchange filing::JPMORGAN CHASE & CO'S LONG POSITION IN CANSINO BIOLOGICS <<<6185.HK>>> DECREASED TO 6.96% ON FEB 16 FROM 9.71% - HKEX FILING.

Capital Group Companies Sold H-Shares In CanSino Biologics On Feb 16 - HKEx Filing

Feb 18 (Reuters) - Hong Kong stock exchange filing::THE CAPITAL GROUP COMPANIES SOLD 555,000 H-SHARES IN CANSINO BIOLOGICS <<<6185.HK>>> AT AVG PRICE OF HK$403.97 ($52.11) PER SHARE ON FEB 16 - HKEX FILING.THE CAPITAL GROUP COMPANIES' LONG POSITION IN CANSINO BIOLOGICS FALLS TO 19.68% FROM 20.10% - HKEX FILING.

Cansino Biologics Inc Sees FY Net Losses Attributable To Be From RMB400.0 Mln To RMB430.0 Mln

Feb 17 (Reuters) - Cansino Biologics Inc <6185.HK>::SEES FY NET LOSSES ATTRIBUTABLE TO BE RMB400.0 MILLION TO RMB430.0 MILLION.SEES RESEARCH AND DEVELOPMENT EXPENDITURE FOR FY TO BE RMB440.0 MILLION TO RMB470.0 MILLION.SEES NET LOSSES ATTRIBUTABLE AFTER DEDUCTING NON-RECURRING PROFIT & LOSS FOR YEAR RMB510.0 MILLION TO RMB540.0 MILLION, UP 192.4% TO 209.6%.EXPECTED FY RESULT DUE TO INCREASED RESEARCH AND DEVELOPMENT EXPENDITURE FOR RECOMBINANT COVID-19 VACCINE.

The Capital Group Companies Inc Bought H-Shares In CanSino Biologics On Feb 8 - HKEX Filing

Feb 10 (Reuters) - Hong Kong stock exchange filing::THE CAPITAL GROUP COMPANIES INC BOUGHT 258,824 H-SHARES IN CANSINO BIOLOGICS <<<6185.HK>>> AT AVG PRICE OF HK$358.03 ($46.18) PER SHARE ON FEB 8 - HKEX FILING.THE CAPITAL GROUP COMPANIES INC'S LONG POSITION IN CANSINO BIOLOGICS RISES TO 20.05% FROM 19.86% - HKEX FILING.

Cansino Says Ad5-nCOV Approved By Federal Commission For Protection Against Sanitary Risks Of Mexico

Feb 10 (Reuters) - Cansino Biologics Inc <6185.HK>::AD5-NCOV APPROVED BY FEDERAL COMMISSION FOR PROTECTION AGAINST SANITARY RISKS OF MEXICO.

Solution Group Says Unit Signed Term Sheet Deal With Govt Of Malaysia For Supply Of COVID-19 Vaccine

Feb 4 (Reuters) - Solution Group Bhd <SLEG.KL>::UNIT SIGNED TERM SHEET AGREEMENT WITH GOVERNMENT OF MALAYSIA FOR SUPPLY OF COVID-19 VACCINE.VACCINE JOINTLY DEVELOPED BY CANSINO BIOLOGICS & BEIJING INSTITUTE OF BIOTECHNOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES.TERM SHEET AGREEMENT IS EXPECTED TO CONTRIBUTE POSITIVELY TO FUTURE EARNINGS AND EPS FOR FY ENDING 31 DEC 2021.

Cansino Biologics Updates On Phase III Clinical Trial Of Recombinant Covid-19 Vaccine

Feb 1 (Reuters) - Cansino Biologics Inc <6185.HK>::UPDATES ON PROGRESS ON PHASE III CLINICAL TRIAL OF- RECOMBINANT COVID-19 VACCINE.INFORMED BY IDMC THAT AD5-NCOV SUCCESSFULLY MET PRE-SPECIFIED PRIMARY SAFETY AND EFFICACY CRITERIA AT INTERIM ANALYSIS..TO CONTINUE TO ADVANCE PHASE III CLINICAL TRIAL OF AD5-NCOV.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up